Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
IFF
International Flavors & Fragrances Inc.
DEB and enzyme-based biotechnologies are core to IFF's Health & Biosciences innovation and product offerings.
|
$20.02B |
$78.37
+0.23%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$19.61B |
$103.50
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$19.56B |
$99.61
-1.56%
|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$19.41B |
$97.42
-1.45%
|
|
BWXT
BWX Technologies, Inc.
Radiopharmaceuticals for nuclear medicine imaging and diagnostics.
|
$18.79B |
$201.40
-2.03%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$18.09B |
$27.61
-2.02%
|
|
WST
West Pharmaceutical Services, Inc.
West generates revenue from contract manufacturing services, moving towards higher-margin opportunities.
|
$17.90B |
$249.07
+0.09%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$17.09B |
$240.25
-1.09%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$16.94B |
$14.47
-1.60%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$14.75B |
$238.75
-1.09%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.30B |
$132.16
-0.96%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$13.12B |
$467.04
+0.25%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.87B |
$77.93
-1.91%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$12.82B |
$65.62
-1.38%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$12.58B |
$25.25
-0.79%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$12.14B |
$23.82
-2.54%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.89B |
$14.23
-0.35%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$11.72B |
$92.31
-0.76%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$11.61B |
$60.38
-0.07%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$11.47B |
$186.87
-0.96%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$11.45B |
$15.07
-2.02%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.18B |
$41.03
-1.58%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$10.21B |
$46.53
-0.75%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$9.87B |
$440.18
+1.24%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$9.78B |
$18.73
-1.58%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$9.69B |
$64.02
-2.49%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$9.01B |
$57.90
+0.09%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.99B |
$135.38
-1.21%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$8.86B |
$9.04
+0.44%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$8.84B |
$63.83
-1.96%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$8.84B |
$179.70
+0.07%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$8.57B |
$110.01
-0.17%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
Showing page 3 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
